Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

Lu Xie; Jie Xu; Xin Sun; Wei Guo; Jin Gu; Kuisheng Liu; Bingxin Zheng; Tingting Ren; Yi Huang; Xiaodong Tang; Taiqiang Yan; Rongli Yang; Kunkun Sun; Danhua Shen; Yuan Li

doi:10.1136/jitc-2020-000798

Article metrics

This article has a correction. Please see:

Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial - June 01, 2020

PDF

XML

Clinical/translational cancer immunotherapy

Original research

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial

Online download statistics by month:

Online download statistics by month: May 2020 to April 2023

	Abstract	Full	Pdf
May 2020	313	313	140
Jun 2020	153	153	54
Jul 2020	69	69	37
Aug 2020	61	59	19
Sep 2020	53	53	24
Oct 2020	41	41	35
Nov 2020	44	45	56
Dec 2020	26	26	9
Jan 2021	44	43	30
Feb 2021	57	57	44
Mar 2021	60	60	23
Apr 2021	36	35	27
May 2021	37	37	22
Jun 2021	43	43	21
Jul 2021	66	66	37
Aug 2021	57	57	45
Sep 2021	59	59	44
Oct 2021	82	82	58
Nov 2021	61	61	55
Dec 2021	50	50	43
Jan 2022	65	69	33
Feb 2022	46	47	43
Mar 2022	62	72	42
Apr 2022	64	68	33
May 2022	61	66	36
Jun 2022	57	58	24
Jul 2022	45	47	33
Aug 2022	56	56	37
Sep 2022	46	46	32
Oct 2022	52	56	29
Nov 2022	32	34	22
Dec 2022	47	48	29
Jan 2023	40	40	27
Feb 2023	88	88	33
Mar 2023	61	62	28
Apr 2023	46	46	22
Total	2280	2312	1326

Log in using your username and password

Main menu

Log in using your username and password

You are here

This article has a correction. Please see:

Online download statistics by month:

Online download statistics by month: May 2020 to April 2023

Read the full text or download the PDF:

Log in using your username and password